Latest On Kintara Therapeutics, Inc (DMPI):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-02-14 07:29 EST | Financials | Company financials have been released. | Neutral |  |
| 2020-12-06 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 19:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-20 03:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 03:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 15:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 12:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-25 00:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 00:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-23 00:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 04:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-31 20:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-21 16:49 EST | Insider Trade | Keith Murphy has directly acquired 181,010 shares and currently holds 181,010 shares. | Buy | |
| 2020-08-21 16:49 EST | Insider Trade | John Liatos has directly acquired 196,750 shares and currently holds 196,750 shares. | Buy | |
| 2020-08-19 11:14 EST | News | DelMar Pharma announces ~$20M capital raise | N/A | |
| 2020-08-18 06:29 EST | News | Delmar +7.8% PM, stockholders approve all proposals regarding Delmar and Adgero merger | N/A | |
| 2020-08-14 08:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-17 16:14 EST | News | Denovo Biopharma's enzastaurin Fast Track'd for brain tumor | N/A | |
| 2020-07-09 08:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 10:24 EST | News | DelMar Pharma secures $500K loan to support advancement of VAL-083 | N/A | |
| 2020-06-23 00:18 EST | News | DelMar Pharma down 17% on underwhelming VAL-083 data | N/A | |
| 2020-06-12 04:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-11 05:28 EST | News | DelMar Pharma rallies on acquisition of Adgero Bio | N/A | |
| 2020-05-27 04:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-17 20:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-13 11:36 EST | News | DelMar Pharmaceuticals EPS misses by $0.01 | N/A | |
| 2020-05-06 04:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-03 08:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-11 12:30 EST | News | DelMar Pharmaceuticals EPS beats by $0.10 | N/A | |
| 2020-04-11 12:26 EST | News | DelMar Pharma up 4% advancement of VAL-083 study | N/A | |
| 2020-04-10 00:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-07 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-22 00:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 20:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-15 23:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-14 23:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-14 03:27 EST | Earnings | Earnings have been released on February 13, 2020, with -$0.15 earnings per share. | Buy | |
| 2020-02-14 03:27 EST | Earnings Estimate | An EPS average of -$0.12 is estimated for the quarter ending on March 31, 2020. | Buy | |
| 2020-02-12 23:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-31 23:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 03:39 EST | Earnings | Earnings have been released on February 12, 2019, with -$0.75 earnings per share. | Buy | |
| 2020-01-28 03:39 EST | Earnings | Earnings have been released on November 14, 2018, with -$0.88 earnings per share. | Buy | |
| 2020-01-28 03:39 EST | Earnings | Earnings have been released on September 10, 2019, with -$0.89 earnings per share. | Sell | |
| 2020-01-28 03:39 EST | Earnings | Earnings have been released on May 15, 2019, with -$0.67 earnings per share. | Buy | |
About Kintara Therapeutics, Inc (DMPI):
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Its product candidate is VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California.
General
- Name Kintara Therapeutics, Inc
- Symbol DMPI
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 2
- Last Split Factor1:10
- Last Split Date2019-05-08
- Fiscal Year EndJune
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.delmarpharma.com
View More
Valuation
- Price/Book (Most Recent Quarter) 11.02
View More
Financials
- Most Recent Quarter 2020-09-30
- Return on Assets -137%
- Earnings Per Share -$3.16
- Revenue Per Share $0
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 15.35 million
- EBITDA -8382147
- Analyst Target Price $3
- Book Value Per Share $0.20
View More
Share Statistics
- Shares Outstanding 11.46 million
- Shares Float 10.64 million
- % Held by Insiders 144%
- % Held by Institutions 12.46%
- Shares Short 211710
- Shares Short Prior Month 458076
- Short Ratio 0.24
- Short % of Float 2%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 1.85
- 52 Week High $2.5
- 52 Week Low $0.38
- 50 Day Moving Average 1.49
- 200 Day Moving Average 1.36
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
View More
Kintara Therapeutics, Inc (DMPI) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Kintara Therapeutics, Inc (DMPI) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-12 | $N/A | -$1.33 | -$0.09 | -1377.78% |
| 2020-06-30 | 2020-09-08 | $N/A | -$0.33 | -$0.13 | -153.85% |
| 2020-03-31 | 2020-05-13 | $N/A | -$0.17 | -$0.12 | -41.67% |
| 2019-12-31 | 2020-02-13 | $N/A | -$0.15 | -$0.17 | 11.76% |
| 2019-09-30 | 2019-11-13 | $N/A | -$0.21 | ||
| 2019-06-30 | 2019-09-09 | $N/A | -$0.89 | -$0.61 | -45.9% |
| 2019-03-31 | 2019-05-14 | $N/A | -$0.67 | ||
| 2018-12-31 | 2019-02-11 | $N/A | -$0.75 | ||
| 2018-09-30 | 2018-11-13 | $N/A | -$0.88 | ||
| 2018-06-30 | 2018-09-24 | $N/A | -$1.00 | -$1.10 | 9.09% |
| 2018-03-31 | 2018-05-15 | $N/A | -$1.30 | -$1.00 | -30% |
| 2017-12-31 | 2018-02-14 | $N/A | -$1.40 | -$1.50 | 6.67% |
| 2017-09-30 | 2017-11-09 | $N/A | -$1.80 | -$1.70 | -5.88% |
| 2017-06-30 | 2017-09-27 | $N/A | -$0.20 | -$0.16 | -25% |
| 2017-03-31 | 2017-05-12 | $N/A | -$0.18 | -$0.14 | -28.57% |
| 2016-12-31 | 2017-02-10 | $N/A | -$0.13 | -$0.22 | 40.91% |
| 2016-09-30 | 2016-11-14 | $N/A | -$0.23 | -$0.15 | -53.33% |
| 2016-06-30 | 2016-09-13 | $N/A | -$0.32 | -$0.19 | -68.42% |
| 2016-03-31 | 2016-05-13 | $N/A | -$0.12 | -$0.19 | 36.84% |
| 2015-12-31 | 2016-02-12 | $N/A | -$0.24 | -$0.12 | -100% |
| 2015-09-30 | 2015-11-16 | $N/A | -$0.16 | -$0.12 | -33.33% |
| 2015-06-30 | 2015-09-04 | $N/A | -$0.30 | ||
| 2015-03-31 | 2015-05-18 | $N/A | -$0.12 | -$0.32 | 62.5% |
| 2014-12-31 | 2015-02-12 | $N/A | -$0.08 | -$0.24 | 66.67% |
| 2014-09-30 | 2014-11-10 | $N/A | -$1.45 | ||
| 2014-06-30 | 2014-08-29 | $N/A | $4.03 | ||
| 2014-03-31 | 2014-03-31 | $N/A | -$4.04 | ||
| 2013-12-31 | 2014-03-10 | $N/A | -$0.80 | -$2.00 | 60% |
| 2013-09-30 | 2013-09-30 | $N/A | $6.52 | ||
| 2013-06-30 | 2013-06-30 | $N/A | -$8.80 | ||
| 2013-03-31 | 2013-03-31 | $N/A | -$12.18 |
Kintara Therapeutics, Inc (DMPI) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Research Development | 2.58 million | 17.45 million | 1.3 million | 898720 | 898720 |
| Income Before Tax | -5.41 million | -19.52 million | -3.82 million | -1.96 million | -1.96 million |
| Selling General Administrative | 2.79 million | 1.53 million | 1.47 million | 1.08 million | 1.08 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | -5.41 million | -19.51 million | -2.77 million | -1.97 million | -1.97 million |
| Operating Income | -5.38 million | -18.99 million | -2.77 million | -1.98 million | -1.98 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | -499000 | -1.06 million | 2416 | 2416 |
| Net Income From Continuing Operations | -5.41 million | -19.52 million | -3.82 million | -1.96 million | -1.96 million |
| Net Income Applicable to Common Shares | -5.42 million | N/A | N/A | N/A | -1.96 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Investments | 969000 | N/A | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | N/A | 334820 | -376792 |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | 23.35 million | -2089 | -2089 | -2089 | -2089 |
| Change to Operating Activities | N/A | N/A | N/A | 47875 | 206262 |
| Change in Cash | 20.21 million | -2.58 million | -1.37 million | -1.37 million | -1.71 million |
| Total Cash from Operating Activities | -4.11 million | -2.58 million | -1.37 million | -1.37 million | -1.71 million |
| Depreciation | 1000 | 1550 | 2801 | 2801 | 5602 |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | N/A | 198915 | 197868 |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | 2.9 million | 2.58 million | 2.67 million | 1.38 million | N/A |
| Total Stockholder Equity | 21.84 million | 20.55 million | 263214 | 3.72 million | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | 3.72 million |
| Total Assets | 20.49 million | 23.13 million | 2.94 million | 5.1 million | N/A |
| Common Stock | 25000 | N/A | N/A | N/A | N/A |
| Other Current Assets | 559000 | N/A | N/A | N/A | 11427 |
| Retained Earnings | -97.85 million | -92.43 million | -69.72 million | -65.89 million | -65.89 million |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A |
| Cash | 17.16 million | 22.6 million | 2.39 million | 4.97 million | 4.97 million |
| Total Current Liabilities | 2.73 million | 2.39 million | 2.67 million | 1.38 million | 1.38 million |
| Other Stockholder Equity | 21000 | N/A | N/A | N/A | 8.4 million |
| Property, Plant & Equipment | 172000 | N/A | N/A | N/A | N/A |
| Total Current Assets | 17.72 million | 22.96 million | 2.85 million | 5.1 million | 5.1 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | -4.25 million | N/A | N/A | N/A | -1.09 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 2.25 million | 1.57 million | 2.01 million | 1.09 million | 1.09 million |
Kintara Therapeutics, Inc (DMPI) Chart:
Kintara Therapeutics, Inc (DMPI) News:
Below you will find a list of latest news for Kintara Therapeutics, Inc (DMPI) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Kintara Therapeutics, Inc (DMPI) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Kintara Therapeutics, Inc (DMPI) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1498382/000119312520186917/0001193125-20-186917-index.htm |
| 2020-06-23 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1498382/000000000020005608/0000000000-20-005608-index.htm |
| 2020-01-23 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000090266420000411/0000902664-20-000411-index.htm |
| 2019-09-19 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000779/0000905718-19-000779-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000809/0000905718-19-000809-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000811/0000905718-19-000811-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000813/0000905718-19-000813-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000815/0000905718-19-000815-index.htm |
| 2019-10-01 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000817/0000905718-19-000817-index.htm |
| 2019-11-14 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571819000941/0000905718-19-000941-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000012/0000905718-20-000012-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000014/0000905718-20-000014-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000016/0000905718-20-000016-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000018/0000905718-20-000018-index.htm |
| 2020-01-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000020/0000905718-20-000020-index.htm |
| 2020-08-27 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000905/0000905718-20-000905-index.htm |
| 2020-08-28 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000907/0000905718-20-000907-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000961/0000905718-20-000961-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000963/0000905718-20-000963-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000965/0000905718-20-000965-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000967/0000905718-20-000967-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000969/0000905718-20-000969-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000971/0000905718-20-000971-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000973/0000905718-20-000973-index.htm |
| 2020-09-17 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000975/0000905718-20-000975-index.htm |
| 2020-09-24 | 4/A | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000982/0000905718-20-000982-index.htm |
| 2020-09-24 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000984/0000905718-20-000984-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000997/0000905718-20-000997-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000998/0000905718-20-000998-index.htm |
| 2020-09-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000090571820000999/0000905718-20-000999-index.htm |
| 2020-02-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000110465920013406/0001104659-20-013406-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000119312520038091/0001193125-20-038091-index.htm |
| 2020-06-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000119312520165187/0001193125-20-165187-index.htm |
| 2020-06-10 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000119312520165188/0001193125-20-165188-index.htm |
| 2020-06-16 | S-4 | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000119312520170505/0001193125-20-170505-index.htm |
| 2020-06-24 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000119312520177765/0001193125-20-177765-index.htm |
| 2020-06-24 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000119312520177766/0001193125-20-177766-index.htm |
| 2020-06-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000119312520181055/0001193125-20-181055-index.htm |
| 2020-06-30 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1498382/000119312520184125/0001193125-20-184125-index.htm |
| 2020-07-02 | S-4/A | Registration of securities, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000119312520185478/0001193125-20-185478-index.htm |
| 2020-07-02 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1498382/000119312520186917/0001193125-20-186917-index.htm |
| 2019-09-27 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390019019207/0001213900-19-019207-index.htm |
| 2019-10-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390019019391/0001213900-19-019391-index.htm |
| 2019-11-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1498382/000121390019023215/0001213900-19-023215-index.htm |
| 2019-11-15 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1498382/000121390019023736/0001213900-19-023736-index.htm |
| 2019-11-15 | POS AM | Post-Effective amendments for registration statement | https://www.sec.gov/Archives/edgar/data/1498382/000121390019023744/0001213900-19-023744-index.htm |
| 2019-11-21 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1498382/000121390019024249/0001213900-19-024249-index.htm |
| 2019-11-21 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1498382/000121390019024251/0001213900-19-024251-index.htm |
| 2019-11-22 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390019024405/0001213900-19-024405-index.htm |
| 2020-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020000327/0001213900-20-000327-index.htm |
| 2020-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000121390020003194/0001213900-20-003194-index.htm |
| 2020-02-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1498382/000121390020003470/0001213900-20-003470-index.htm |
| 2020-02-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020003471/0001213900-20-003471-index.htm |
| 2020-03-26 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020007428/0001213900-20-007428-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020008213/0001213900-20-008213-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020008214/0001213900-20-008214-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020008217/0001213900-20-008217-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020008219/0001213900-20-008219-index.htm |
| 2020-03-31 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020008229/0001213900-20-008229-index.htm |
| 2020-04-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020009703/0001213900-20-009703-index.htm |
| 2020-05-13 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1498382/000121390020011910/0001213900-20-011910-index.htm |
| 2020-05-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020011912/0001213900-20-011912-index.htm |
| 2020-06-02 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1498382/000121390020013923/0001213900-20-013923-index.htm |
| 2020-06-08 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1498382/000121390020014311/0001213900-20-014311-index.htm |
| 2020-06-11 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1498382/000121390020014692/0001213900-20-014692-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016299/0001213900-20-016299-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016303/0001213900-20-016303-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016306/0001213900-20-016306-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016308/0001213900-20-016308-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016310/0001213900-20-016310-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016315/0001213900-20-016315-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016317/0001213900-20-016317-index.htm |
| 2020-06-30 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016319/0001213900-20-016319-index.htm |
| 2020-07-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020016559/0001213900-20-016559-index.htm |
| 2020-07-28 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000121390020018865/0001213900-20-018865-index.htm |
| 2020-08-17 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020022409/0001213900-20-022409-index.htm |
| 2020-08-17 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000121390020022410/0001213900-20-022410-index.htm |
| 2020-08-18 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1498382/000121390020022614/0001213900-20-022614-index.htm |
| 2020-08-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023261/0001213900-20-023261-index.htm |
| 2020-08-21 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023264/0001213900-20-023264-index.htm |
| 2020-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023271/0001213900-20-023271-index.htm |
| 2020-08-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023272/0001213900-20-023272-index.htm |
| 2020-08-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023287/0001213900-20-023287-index.htm |
| 2020-08-24 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023471/0001213900-20-023471-index.htm |
| 2020-08-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023568/0001213900-20-023568-index.htm |
| 2020-09-01 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000121390020024674/0001213900-20-024674-index.htm |
| 2020-08-28 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000149315220016923/0001493152-20-016923-index.htm |
| 2020-01-21 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1498382/000153561020000042/0001535610-20-000042-index.htm |
| 2020-09-18 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1498382/000156459020044019/0001564590-20-044019-index.htm |
| 2020-09-21 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1498382/000156459020044027/0001564590-20-044027-index.htm |
| 2020-09-21 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1498382/000156459020044055/0001564590-20-044055-index.htm |
| 2020-10-26 | S-3 | Registration statement under Securities Act of 1933 | https://www.sec.gov/Archives/edgar/data/1498382/000156459020047646/0001564590-20-047646-index.htm |
| 2020-11-04 | 424B4 | Prospectus [Rule 424(b)(4)] | https://www.sec.gov/Archives/edgar/data/1498382/000156459020050543/0001564590-20-050543-index.htm |
| 2019-11-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1498382/999999999519002617/9999999995-19-002617-index.htm |
| 2019-11-20 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1498382/999999999519002618/9999999995-19-002618-index.htm |
| 2020-07-02 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1498382/999999999520001631/9999999995-20-001631-index.htm |
| 2020-11-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1498382/999999999520003083/9999999995-20-003083-index.htm |
Kintara Therapeutics, Inc (DMPI) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kintara Therapeutics, Inc (DMPI). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 144%Institutional Ownership: 1246%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-08-19 | Keith Murphy | Director | Buy | 181,010.00 | 181,010.00 | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023271/0001213900-20-023271-index.htm | ||
| 2020-08-19 | John Liatos | SVP, Business Development | Buy | 196,750.00 | 196,750.00 | https://www.sec.gov/Archives/edgar/data/1498382/000121390020023272/0001213900-20-023272-index.htm |